2021 – UK market access prospectsWith a new year comes the opportunity to think ahead for the market access landscape for the coming Share X2021 – UK market access prospectshttps://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/
EMA says AstraZeneca’s COVID-19 shot could be approved on 29 JanuaryThe European medicines Agency (EMA) said this morning it has received a marketing application from AstraZeneca for its Share XEMA says AstraZeneca’s COVID-19 shot could be approved on 29 Januaryhttps://pharmaphorum.com/news/ema-says-astrazenecas-covid-19-shot-could-be-approved-on-29-january/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Moderna’s COVID-19 vaccine is third approved in UKThe UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although Share XModerna’s COVID-19 vaccine is third approved in UKhttps://pharmaphorum.com/news/modernas-covid-19-vaccine-is-third-approved-in-uk/
Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerNICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in Share XUnconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerhttps://pharmaphorum.com/news/unconvinced-by-nhs-test-run-nice-rejects-bms-opdivo-in-head-and-neck-cancer/
UK left trailing as EU quickly approves Moderna’s COVID-19 vaccineThe European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to Share XUK left trailing as EU quickly approves Moderna’s COVID-19 vaccinehttps://pharmaphorum.com/news/uk-left-trailing-as-eu-quickly-approves-modernas-covid-19-vaccine/
Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
Nine for 2021: The COVID-19 legacyIn the first of a two part series, IQVIA’s Sarah Rickwood covers nine key trends and events that Share XNine for 2021: The COVID-19 legacyhttps://pharmaphorum.com/views-and-analysis/nine-for-2021-the-covid-19-legacy/
FDA and doctors warn against extending COVID-19 vaccine dose gapTinkering with the dosing schedule of COVID-19 vaccines runs a “significant risk” to public health, the FDA has Share XFDA and doctors warn against extending COVID-19 vaccine dose gaphttps://pharmaphorum.com/news/fda-and-doctors-warn-against-extending-covid-19-vaccine-dose/
